Open an account

Aditxt

ADTX · NASDAQ

$0.0008−$0.0002 (−20.00%)TodayMarket closed ·
Prev close $0.001

About ADTX

Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. The firm operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and women’s health. Its subsidiaries include Adimune, Inc. (Adimune), Pearsanta, Inc., Adivir, Inc. and Adifem, Inc. Adimune is focused on its immune modulation therapeutic programs. Adimune’s proprietary immune modulation product, Apoptotic DNA Immunotherapy (ADI), utilizes a novel approach that mimics the way its bodies naturally induce tolerance to our own tissues. Adivir, Inc. is focused on building a portfolio of antiviral and other antimicrobial solutions designed to target life-threatening viral infections and emerging pathogens. Pearsanta, Inc. is engaged in the development of molecular tests based on mitochondrial DNA to develop tests for early detection of cancer. The company is also focused on addressing a critical challenge in cancer care: optimizing therapy selection.

Employees
26
Headquarters
Richmond, Virginia
Listed
Jun 19, 2020
Sector
Health Care
Industry
Biotechnology
Website
aditxt.com

ADTX key statistics

Market cap
798.38K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
13.70M
Volume
2.02M
Open price
$0.0006
High today
$0.0009
Low today
$0.0006
52 Week high
$8,542.80
52 Week low
$0.0001

Aditxt (ADTX) at a glance

Aditxt (ADTX) last traded at $0.0008, with a market cap of 798.38K and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.0006 and $0.0009. The current price is 33.3% above the day's low and 11.1% below its high.

Volume so far is 2.02M shares, below the average of 13.70M shares a day.

Over the past year Aditxt has ranged from $0.0001 to $8,542.80, and now sits 0% of the way up that range.

Aditxt met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q3 FY25 it reported -$73.15 per share against an estimate of $0.00.

ADTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 61.3% on average.

  1. Q2 FY22: reported -$63,460,757,504.00 per share against an estimate of $54,764,544,000.00
  2. Q3 FY22: reported -$51,452,067,840.00 per share against an estimate of -$23,551,887,360.00
  3. Q4 FY22: reported -$42,860,449,792.00 per share against an estimate of -$14,738,596,864.00
  4. Q1 FY23: reported -$12,789,792,768.00 per share against an estimate of -$27,684,671,488.00
  5. Q2 FY23: reported -$8,982,144,000.00 per share against an estimate of -$28,780,111,872.00
  6. Q3 FY23: reported -$11,715,840,000.00 per share against an estimate of -$1,986,714,112.00
  7. Q4 FY23: reported -$8,987,025,408.00 per share against an estimate of -$7,421,548,032.00
  8. Q3 FY25: reported -$73.15 per share against an estimate of $0.00

ADTX news

  • Tanya Rawat

    Aditxt (ADTX) Stock Sinks 20% After-Hours: Here’s What’s Going On

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Avi Kapoor

    Nasdaq Surges 300 Points; US Initial Jobless Claims Edge Lower

  • Avi Kapoor

    Crude Oil Edges Higher; US Retail Sales Top Estimates

  • Avi Kapoor

    US Stocks Edge Higher; CarMax Posts Upbeat Earnings

  • Tanya Rawat

    Aditxt (ADTX) Stock Is Falling After Hours: What Is Going On?

  • Mohd Haider

    Aditxt (ADTX) Stock Surges Nearly 17% After Hours: Here's Why

  • Press releaseBusiness Wire

    Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million

Similar companies

Companies in the same industry as Aditxt

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.